Clinical and subclinical acute kidney injury in children with mild-to-moderate COVID-19

被引:13
|
作者
Saygili, Seha [1 ]
Canpolat, Nur [1 ]
Cicek, Rumeysa Yasemin [2 ]
Agbas, Ayse [3 ]
Yilmaz, Esra Karabag [1 ]
Sakalli, Ayse Ayzit Kilinc [4 ]
Aygun, Deniz [5 ]
Akkoc, Gulsen [6 ]
Demirbas, Kaan Can [7 ]
Konukoglu, Dildar [8 ]
Cokugras, Haluk [4 ,9 ]
Caliskan, Salim [1 ]
Sever, Lale [1 ]
机构
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pediat Nephrol, Istanbul, Turkey
[2] Univ Hlth Sci, Kanuni Sultan Suleyman Training & Res Hosp, Dept Pediat Nephrol, Istanbul, Turkey
[3] Univ Hlth Sci, Haseki Training & Res Hosp, Dept Pediat Nephrol, Istanbul, Turkey
[4] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pediat Pulmonol, Istanbul, Turkey
[5] Univ Hlth Sci, Kanuni Sultan Suleyman Training & Res Hosp, Dept Pediat Infect Dis, Istanbul, Turkey
[6] Univ Hlth Sci, Haseki Training & Res Hosp, Dept Pediat Infect Dis, Istanbul, Turkey
[7] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Istanbul, Turkey
[8] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Biochem, Istanbul, Turkey
[9] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pediat Infect Dis, Istanbul, Turkey
关键词
BIOMARKERS; AKI;
D O I
10.1038/s41390-022-02124-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Our aim was to identify acute kidney injury (AKI) and subacute kidney injury using both KDIGO criteria and urinary biomarkers in children with mild/moderate COVID-19. Methods This cross-sectional study included 71 children who were hospitalized with a diagnosis of COVID-19 from 3 centers in Istanbul and 75 healthy children. We used a combination of functional (serum creatinine) and damage (NGAL, KIM-1, and IL-18) markers for the definition of AKI and subclinical AKI. Clinical and laboratory features were evaluated as predictors of AKI and subclinical AKI. Results Patients had significantly higher levels of urinary biomarkers and urine albumin-creatinine ratio than healthy controls (p < 0.001). Twelve patients (16.9%) developed AKI based on KDIGO criteria, and 22 patients (31%) had subclinical AKI. AKI group had significantly higher values of neutrophil count on admission than both subclinical AKI and non-AKI groups (p < 0.05 for all). Neutrophil count was independently associated with the presence of AKI (p = 0.014). Conclusions This study reveals that even children with a mild or moderate disease course are at risk for AKI. Association between neutrophil count and AKI may point out the role of inflammation in the development of AKI. Impact The key message of our article is that not only children with severe disease but also children with mild or moderate disease have an increased risk for kidney injury due to COVID-19. Urinary biomarkers enable the diagnosis of a significant number of patients with subclinical AKI in patients without elevation in serum creatinine. Our findings reveal that patients with high neutrophil count may be more prone to develop AKI and should be followed up carefully. We conclude that even children with mild or moderate COVID-19 disease courses should be evaluated for AKI and subclinical AKI, which may improve patient outcomes.
引用
收藏
页码:654 / 660
页数:7
相关论文
共 50 条
  • [1] Clinical and subclinical acute kidney injury in children with mild-to-moderate COVID-19
    Seha Saygili
    Nur Canpolat
    Rumeysa Yasemin Cicek
    Ayse Agbas
    Esra Karabag Yilmaz
    Ayse Ayzit Kilinc Sakalli
    Deniz Aygun
    Gülsen Akkoc
    Kaan Can Demirbas
    Dildar Konukoglu
    Haluk Cokugras
    Salim Caliskan
    Lale Sever
    Pediatric Research, 2023, 93 : 654 - 660
  • [2] Azithromycin for mild-to-moderate COVID-19
    Hinks, Timothy S. C.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (10): : E100 - E101
  • [3] Could urinary kidney injury molecule-1 be a good marker in subclinical acute kidney injury in mild to moderate COVID-19 infection?
    Emre Yasar
    Hasan Selcuk Ozger
    Hacı Hasan Yeter
    Cigdem Yildirim
    Zakir Osmanov
    Taha Enes Cetin
    Omer Faruk Akcay
    Neslihan Bukan
    Ulver Derici
    International Urology and Nephrology, 2022, 54 : 627 - 636
  • [4] Could urinary kidney injury molecule-1 be a good marker in subclinical acute kidney injury in mild to moderate COVID-19 infection?
    Yasar, Emre
    Ozger, Hasan Selcuk
    Yeter, Haci Hasan
    Yildirim, Cigdem
    Osmanov, Zakir
    Cetin, Taha Enes
    Akcay, Omer Faruk
    Bukan, Neslihan
    Derici, Ulver
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (03) : 627 - 636
  • [5] Distinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19
    Mueller, Michael
    Volzke, Johann
    Subin, Behnam
    Schmidt, Christian Johann
    Geerdes-Fenge, Hilte
    Reisinger, Emil Christian
    Mueller-Hilke, Brigitte
    VIRUSES-BASEL, 2022, 14 (02):
  • [6] Mild-to-Moderate COVID-19 Infection and Myocarditis: A Review
    Bailey, Eric
    Frishman, William H. H.
    CARDIOLOGY IN REVIEW, 2023, 31 (03) : 173 - 175
  • [7] Features of Mild-to-Moderate COVID-19 Patients With Dysphonia
    Lechien, Jerome R.
    Chiesa-Estomba, Carlos M.
    Cabaraux, Pierre
    Mat, Quentin
    Huet, Kathy
    Harmegnies, Bernard
    Horoi, Mihaela
    Le Bon, Serge Daniel
    Rodriguez, Alexandra
    Dequanter, Didier
    Hans, Stephane
    Crevier-Buchman, Lise
    Hochet, Baptiste
    Distinguin, Lea
    Chekkoury-Idrissi, Younes
    Circiu, Marta
    El Afia, Fahd
    Barillari, Maria Rosaria
    Cammaroto, Giovanni
    Fakhry, Nicolas
    Michel, Justin
    Radulesco, Thomas
    Martiny, Delphine
    Lavigne, Philippe
    Jouffe, Lionel
    Descamps, Geraldine
    Journe, Fabrice
    Trecca, Eleonora M. C.
    Hsieh, Julien
    Delgado, Irene Lopez
    Calvo-Henriquez, Christian
    Vergez, Sebastien
    Khalife, Mohamad
    Molteni, Gabriele
    Mannelli, Giuditta
    Cantarella, Giovanna
    Tucciarone, Manuel
    Souchay, Christel
    Leich, Pierre
    Ayad, Tareck
    Saussez, Sven
    JOURNAL OF VOICE, 2022, 36 (02) : 249 - 255
  • [8] Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
    Cavalcanti, A. B.
    Zampieri, F. G.
    Rosa, R. G.
    Azevedo, L. C. P.
    Veiga, V. C.
    Avezum, A.
    Damiani, L. P.
    Marcadenti, A.
    Kawano-Dourado, L.
    Lisboa, T.
    Junqueira, D. L. M.
    de Barros e Silva, P. G. M.
    Tramujas, L.
    Abreu-Silva, E. O.
    Laranjeira, L. N.
    Soares, A. T.
    Echenique, L. S.
    Pereira, A. J.
    Freitas, F. G. R.
    Gebara, O. C. E.
    Dantas, V. C. S.
    Furtado, R. H. M.
    Milan, E. P.
    Golin, N. A.
    Cardoso, F. F.
    Maia, I. S.
    Hoffmann Filho, C. R.
    Kormann, A. P. M.
    Amazonas, R. B.
    Bocchi de Oliveira, M. F.
    Serpa-Neto, A.
    Falavigna, M.
    Lopes, R. D.
    Machado, F. R.
    Berwanger, O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21): : 2041 - 2052
  • [9] Clinical Pathways When Considering Antimicrobials for the Treatment of Mild-to-Moderate COVID-19
    Krauth, Daniel S.
    MILITARY MEDICINE, 2022, 187 (7-8) : 186 - 188
  • [10] Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Moser, Carlee B.
    Li, Jonathan Z.
    Hughes, Michael D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (16): : 1533 - 1535